JPRN-UMIN000002361招募中2 期
Phase II study of modified S-1, docetaxel and cisplatin combination chemotherapy (mDCS) in patients with unresectable metastatic gastric cancer. - Phase II study of mDCS for unresectable metastatic gastric cancer
Tokushima-Hokkaido cancer therapy clinical trial group0 个研究点目标入组 50 人开始时间: 2009年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of hypersensitivity to DCS. 2)Contraindication to TXT, CDDP, S-1, G-CSF. 3)Infectious disease. 4)Severe compliaction. 5)Neuropathy greater than grade 2. 6)Brain metastasis with clinical symptoms. 7)Watery diarea. 8)Active double cancer. 9)Persons to be pregnant or to make pregnant.
研究者
相似试验
招募中
2 期
Phase II study of DCS-Tgastric cancerJPRN-jRCTs061180096Takayama Tetsuji30
招募中
不适用
Phase 2 study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancergastric cancerJPRN-UMIN000012042Tokushima-Hokkaido cancer therapy clinical trial group30
暂停
2 期
A Phase II trial of S-1 and Docetaxel followed by FEC as neoadjuvant chemotherapy for primary breast cancerBreast CancerJPRN-UMIN000005100Keio University School of Medicine40
已完成
1 期
Phase I/II Study of S-1, Cisplatin and Docetaxel in Patients with Advanced Gastric Canceruntreated advanced or recurrent gastric cancerJPRN-UMIN000000484Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama40
已完成
2 期
Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerMetastatic gastric cancer (Advanced or recurrent gastric cancer)JPRN-C000000103Hiroshima Cancer Therapy Development Organization (HiCTDO)50